Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.42 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.41 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.41 |
| ▸ | WEE1 | P30291 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680971 | 0.86 | HTR2C (0.59) | HTR2CHTR6HDAC3HDAC1HDAC6 | |
| SCHEMBL3680498 | 0.79 | HTR6 (0.66) | HTR2CHTR6HRH4 | |
| SCHEMBL3687320 | 0.79 | HTR2C (0.57) | HTR2CHTR6HRH4 | |
| SCHEMBL3687328 | 0.76 | HTR2C (0.64) | HTR2CHTR6HRH4 | |
| SCHEMBL3676460 | 0.76 | HTR2C (0.64) | HTR2CHTR6HRH4PRKD1 | |
| SCHEMBL13170117 | 0.76 | HTR2C (0.64) | HTR2CHTR6HRH4 | |
| SCHEMBL3679652 | 0.76 | HTR2C (0.64) | HTR2CHTR6HRH4 | |
| SCHEMBL3678007 | 0.75 | NCF1 (0.61) | HTR2CHTR6 | |
| SCHEMBL3680463 | 0.75 | HTR2C (0.59) | HTR2CHTR6HRH4 | |
| Hydrochloric Acid SCHEMBL3677880 | 0.75 | HTR2C (0.62) | HTR2CHTR6HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1724267-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197551-A1 | Pyrimidine derivatives | HTR3B, HTR3A, HTR1A | HTR2C 14/4885HTR6 18/4885HDAC3 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.